Sensitizing tumor response to topoisomerase I antibody drug conjugate by selective CDK7 inhibition
Hyerim Jung, Yoonji Lee, DongHoon Yu, Yeejin Jeon, Hwankyu Kang, Dahun Um, Mooyoung Seo, Dongsik Park, Jeongjun Kim, Seung-Joo Lee, Jaeseung Kim, Lauren Escobedo, Yilun Sun, Anish Thomas, Kiyean Nam, Tae-Kyung Kim
This study shows that Q901, a CDK7 inhibitor, enhances cancer susceptibility to TOP1 inhibitors by stabilizing TOP1-DPCs and suppressing DNA repair pathways.
Science Advances · Sep 30, 2026Peer-reviewedCancer Biology